Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes-Reference-Cited by-同舟云学术

Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes

Published:2017-08-09 Issue:402 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Alhadj Ali Mohammad¹^ORCID,Liu Yuk-Fun²³^ORCID,Arif Sefina²,Tatovic Danijela¹,Shariff Hina²^ORCID,Gibson Vivienne B.²,Yusuf Norkhairin²,Baptista Roman²⁴^ORCID,Eichmann Martin²^ORCID,Petrov Nedyalko⁴^ORCID,Heck Susanne⁴,Yang Jennie H. M.²^ORCID,Tree Timothy I. M.²^ORCID,Pujol-Autonell Irma²^ORCID,Yeo Lorraine²,Baumard Lucas²^ORCID,Stenson Rachel¹^ORCID,Howell Alex¹^ORCID,Clark Alison¹^ORCID,Boult Zoe⁵^ORCID,Powrie Jake³,Adams Laura³^ORCID,Wong Florence S.¹^ORCID,Luzio Stephen⁶,Dunseath Gareth⁶,Green Kate⁷^ORCID,O’Keefe Alison⁷^ORCID,Bayly Graham⁷,Thorogood Natasha⁷^ORCID,Andrews Robert⁷,Leech Nicola⁸,Joseph Frank⁹^ORCID,Nair Sunil⁹,Seal Susan⁹^ORCID,Cheung HoYee⁹^ORCID,Beam Craig¹⁰^ORCID,Hills Robert¹¹,Peakman Mark²⁴¹²^ORCID,Dayan Colin M.¹^ORCID

Affiliation:

1. Diabetes Research Group, Cardiff University School of Medicine, Cardiff CF14 4XN, UK.

2. Department of Immunobiology, Faculty of Life Sciences and Medicine, King’s College London, London SE19RT, UK.

3. Department of Diabetes and Endocrinology, Guy’s and St Thomas’ Hospital National Health Service (NHS) Foundation Trust, London SE19RT, UK.

4. National Institute of Health Research Biomedical Research Centre at Guy’s and St Thomas’ Hospital and King’s College London, London SE19RT, UK.

5. Clinical Research Facility, University Hospital of Wales, Cardiff CF14 4XN, UK.

6. Diabetes Research Unit Cymru, Swansea University, Swansea SA2 8PP, UK.

7. Joint Clinical Research Unit, University Hospitals Bristol Foundation Trust, Bristol BS2 8HW, UK.

8. Diabetes and Endocrinology Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle NE1 4LP, UK.

9. Diabetes and Endocrinology Department, Countess of Chester Hospital NHS Foundation Trust, Chester CH2 1UL, UK.

10. Division of Epidemiology and Biostatistics, Western Michigan University School of Medicine, MI 49008, USA.

11. Haematology Clinical Trials Unit, Cardiff University School of Medicine, Cardiff CF14 4XN, UK.

12. King’s Health Partners Institute of Diabetes, Endocrinology and Obesity, London SE19RT, UK.

Abstract

Immunotherapy using peptide from the self-antigen proinsulin is safe in type 1 diabetes and is associated with changes in immune regulation.

Funder

Juvenile Diabetes Research Foundation International

Diabetes UK

Diabetes Vaccine Development Centre

NIHR Biomedical Research Centre

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference34 articles.

1. Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors

2. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function

3. Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010

4. Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase

5. Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms and measures to modulate T cell trafficking for amplified and tolerogenic immunity;Nano Today;2024-02

2. Immunotherapies for Type 1 Diabetes;Textbook of Diabetes;2024-01-12

3. Islet transplantation outcomes in type 1 diabetes and transplantation of HLA-DQ8/DR4: results of a single-centre retrospective cohort in Canada;eClinicalMedicine;2024-01

4. Vaccines for immune tolerance against autoimmune disease;Advanced Drug Delivery Reviews;2023-12

5. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments;Biomedicine & Pharmacotherapy;2023-12